• Mashup Score: 1

    Want to hear the latest news for your cancer type? Patient Power’s events are free and feature cancer experts sharing information for people living with cancer.

    Tweet Tweets with this article
    • Explaining CLL combo therapy to patients, with @MDAndersonNews @NitinJainMD next Tuesday. Join in for live webinar. https://t.co/Sz7Xe5DRH2 #leusm #cll @PatientPower #oncotwitter https://t.co/6x57FSC0Cu

  • Mashup Score: 1

    Want to hear the latest news for your cancer type? Patient Power’s events are free and feature cancer experts sharing information for people living with cancer.

    Tweet Tweets with this article
    • Pleased to be working with @AtriumHealth @LevineCancer and @NGhoshMD providing expert answers for CLL patients in our next live event. https://t.co/tHf8TQNQrg #leusm https://t.co/urEi4bcY3m

  • Mashup Score: 1

    Hear a doctor explain the benefits of sotorasib (Lumakras), the first KRAS G12C inhibitor approved for the treatment of NSCLC.

    Tweet Tweets with this article
    • Way too many cancer patients do not get NGS. Here's a lung cancer expert @DavidHongMD from @MDAndersonNews giving a great example of how critical it is: https://t.co/E3mYpRrIeS #LCSM #lungcancer #NGS @PatientPower

  • Mashup Score: 2

    See posts, photos and more on Facebook.

    Tweet Tweets with this article
    • At #ASCO22, 3 drug combination for CLL. Should patients switch from single agent or does it matter which BTK inhibitor is in the combo? See what @MDAndersonNews Dr. @NitinJainMD has to say: https://t.co/XGZdBYkz1r #leusm #CLL

  • Mashup Score: 1

    Want to hear the latest news for your cancer type? Patient Power’s events are free and feature cancer experts sharing information for people living with cancer.

    Tweet Tweets with this article
    • With BTK and BCL2 inhibitors coming as approved for #CLL how do they work and who is it right for? @TaylorJ_MD explains to me and other patients live TUESDAY #leusm @PatientPower https://t.co/hVnR7zu2dr https://t.co/RniRD0McmR